(GILD) Gilead Sciences, Inc. ANSOFF Analysis Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(GILD) Gilead Sciences, Inc. Bundle
Go Beyond the Preview—Access the Full Ansoff Matrix Analysis
This Gilead Sciences, Inc. Ansoff Matrix Analysis maps growth options across market penetration, market development, product development, and diversification to support strategy, investment, or planning decisions. The page includes a genuine preview of the analysis so you can review style and substance before buying; purchase the full version to receive the complete ready-to-use report.
Market Penetration
Biktarvy HIV treatment share
Biktarvy remains Gilead Sciences, Inc.'s core HIV brand, with 2024 sales of about $13.4 billion and HIV product revenue near $19.6 billion. Gilead uses it to deepen use in the United States, Europe, and other markets, supporting retention across a large, mature HIV base and strong prescriber loyalty.
Descovy PrEP uptake
Descovy supports Gilead Sciences, Inc.'s prevention push in existing HIV markets, and it stays tied to treatment brands like Biktarvy and Odefsey across the care path. In the U.S., it remains the only FDA-approved PrEP option for cisgender men and transgender women at risk, which helps Gilead keep the same patient base as people switch or stay on therapy. That mix supports retention more than pure new-customer growth.
Legacy HIV brand retention
Gilead Sciences, Inc. keeps Genvoya, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla in the commercial HIV mix to defend its installed base. These 6 legacy brands help retain clinics, payers, and long-term patients already inside Gilead Sciences, Inc.’s system. That is market penetration: protecting existing demand, not chasing new categories.
HCV franchise defense
Gilead Sciences, Inc. uses Epclusa, Harvoni, Vosevi, Vemlidy, and Viread to defend share in hepatitis C and liver care, a classic market penetration move. In 2024, Gilead reported $28.8 billion in total revenue, so keeping this legacy franchise active still matters. The portfolio helps retain prescribers and patients already in its ecosystem, rather than chasing new disease areas.
- Defends share with known brands
- Keeps HCV switch risk lower
- Supports repeat use in liver care
- Uses an established revenue base
Cell therapy and oncology share building
Yescarta, Tecartus, Trodelvy, and Zydelig deepen Gilead Sciences, Inc.'s reach in oncology and cell therapy, where Yescarta and Trodelvy are the main growth engines. In 2024, Yescarta delivered $1.7 billion in product sales and Trodelvy $1.3 billion, showing strong use in major cancer centers and supporting specialist adoption in high-value settings.
- Yescarta: $1.7 billion sales
- Trodelvy: $1.3 billion sales
- Tecartus expands hematologic reach
- Zydelig supports legacy oncology presence
Gilead’s HIV Franchise Wins by Defending, Not Expanding
Gilead Sciences, Inc. drives market penetration by pushing Biktarvy, Descovy, and older HIV brands deeper into an already large base; HIV product revenue was about $19.6 billion in 2024, with Biktarvy at about $13.4 billion. That shows retention, switching, and share defense more than new market creation.
| Brand | 2024 Sales | Role |
|---|---|---|
| Biktarvy | $13.4B | Core HIV share |
| Yescarta | $1.7B | Oncology depth |
| Trodelvy | $1.3B | Specialist use |
What is included in the product
Detailed Word Document
Provides a clear Ansoff Matrix framework for analyzing Gilead Sciences, Inc.’s growth strategy across products and markets
Editable Excel File
Provides a clear Gilead Sciences Ansoff Matrix snapshot to quickly align growth strategy across existing and new drugs, markets, and partnerships.
Reference Sources
Lists primary, reputable Gilead sources that link each Ansoff growth path to traceable references for faster, defensible strategy and due diligence.
Market Development
U.S. and Europe HIV expansion
Gilead Sciences, Inc. can grow HIV sales by pushing approved brands into more U.S. and European markets, not by changing the product mix. The HIV franchise already anchors the business, with Biktarvy and Descovy driving adoption, so wider country coverage can lift volume with low R&D spend. That is classic market development: same therapies, broader geography.
International hepatitis C rollout
Gilead Sciences, Inc. can use Epclusa, Harvoni, Vosevi, Vemlidy, and Viread to push hepatitis C and liver-disease sales into more international markets, a classic market development move with existing drugs.
WHO says about 50 million people live with chronic hepatitis C worldwide, with roughly 1.0 million new infections each year, so demand still exists outside Gilead Sciences, Inc.'s core markets.
That gives Gilead Sciences, Inc. room to expand access and win new country launches without needing a new molecule.
Global Veklury access
Veklury extends Gilead Sciences, Inc. beyond HIV and liver disease into acute-care COVID-19 treatment, with approvals in more than 50 countries. Its IV use lets Gilead sell through hospitals and health systems already in its commercial footprint, expanding into new care settings without a new molecule. That makes it a clear market development move: same product, more geographies and treatment channels.
Cell therapy geography expansion
Yescarta and Tecartus give Gilead Sciences, Inc. a clear cell therapy geography expansion path: both can scale in markets with approved CAR-T sites, leukapheresis capacity, and trained oncology teams. In 2024, Yescarta generated about $1.6 billion and Tecartus about $0.4 billion, showing real demand beyond the U.S. Gilead’s global commercial base helps widen country-level access where specialist centers already exist.
- Targets countries with CAR-T centers
- Uses Gilead's global sales footprint
- Builds on Yescarta and Tecartus demand
Partner-led entry into new geographies
Gilead Sciences uses partner-led expansion to move approved science into new geographies faster, with alliances spanning Japan Tobacco, Janssen, Galapagos, and Merck. In FY2024, Gilead posted $28.8 billion in revenue, so even small gains in market reach can matter. This model fits markets where local registration, launch, and channel access need a local partner.
Partners help Gilead turn one asset into multi-country sales without building a full direct footprint first. It also lowers execution risk in markets that need local regulatory know-how. One line: the deal network is a distribution tool, not just an R&D tool.
- Expands reach across borders
- Uses approved assets faster
- Fits local launch-heavy markets
- Lifts scale with less capital
Gilead’s Growth Play: Expand Proven Drugs Into New Markets
Gilead Sciences, Inc. uses market development by taking approved drugs into more countries and care settings, not by changing the molecule. HIV, hepatitis C, COVID-19, and CAR-T products all fit this model.
| Metric | FY2024 |
|---|---|
| Revenue | $28.8B |
| Yescarta | $1.6B |
| Tecartus | $0.4B |
| HCV cases | 50M |
Full Version Awaits
Gilead Sciences, Inc. Reference Sources
This is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full Ansoff Matrix report you'll get, covering market penetration, product development, market development, and diversification strategies for Gilead. Buy to unlock the full, editable version.
Product Development
Biktarvy single-tablet innovation
Biktarvy is Gilead Sciences, Inc.'s single-tablet HIV regimen and a core product in its mature HIV franchise. It brought in $13.4 billion in 2024 sales, showing how one-pill dosing still drives strong share in existing markets. This is product development in the Ansoff Matrix: Gilead keeps improving the same market with a simpler, stickier format.
Veklury intravenous antiviral
Veklury (remdesivir) extends Gilead Sciences, Inc. beyond HIV into a branded antiviral for hospital-based COVID-19 care. The IV formulation fits product development: it uses Gilead Sciences, Inc.’s existing commercial and medical network, but with a newer therapy. In 2025, the drug still supports a non-HIV revenue stream after peak pandemic demand, helping diversify the portfolio.
Trodelvy oncology expansion
Trodelvy pushed Gilead Sciences, Inc. beyond antivirals and into oncology, where it reported about $1.3 billion in 2024 product sales. The drug expands Gilead Sciences, Inc. in treated cancer markets where it already sells specialist medicines, so this fits Product Development in the Ansoff Matrix. In 2025, Trodelvy remained a key growth driver in a high-growth solid-tumor area.
CAR-T portfolio build-out
Gilead Sciences, Inc. is building out CAR-T through Yescarta and Tecartus, two autologous cell therapies for blood cancers used in specialist centers. Yescarta is approved for large B-cell lymphomas, while Tecartus targets mantle cell lymphoma and B-cell precursor acute lymphoblastic leukemia, widening Gilead Sciences, Inc. beyond small-molecule and antiviral drugs.
- Advanced oncology platform, not just one asset
- Specialist-center delivery raises clinical moat
- Deepens pipeline in blood cancer care
Collaborative pipeline advancement
Gilead Sciences, Inc. uses collaborative pipeline advancement to turn its 12 named alliances with Arcus Biosciences, Pionyr Immunotherapeutics, Tizona Therapeutics, Tango Therapeutics, Jounce Therapeutics, Galapagos, Janssen, Japan Tobacco, Gadeta, Bristol-Myers Squibb, Dragonfly Therapeutics, and Merck into new therapies for current markets.
This is classic product development in the Ansoff Matrix: the Company keeps the same core markets in oncology, immunology, and related fields, but expands the menu of treatments through partnered R&D rather than solo build-out.
These deals matter because they spread scientific risk, add fresh assets to the pipeline, and speed access to areas where Gilead already sells or plans to sell.
- 12 active partners fuel pipeline depth
- Focus stays on existing therapeutic markets
- Partnerships cut discovery risk and time
Gilead Grows by Expanding Core Drugs and Pipeline
Gilead Sciences, Inc. uses product development to deepen its core HIV and oncology franchises with newer formats and expanded labels. Biktarvy, Trodelvy, Veklury, and CAR-T assets like Yescarta and Tecartus show the same-market, new-product play. Partnered R&D also adds pipeline breadth without full solo risk.
| Asset | 2024 Sales | Role |
|---|---|---|
| Biktarvy | $13.4B | HIV core |
| Trodelvy | $1.3B | Oncology growth |
Diversification
Oncology beyond antivirals
Gilead Sciences, Inc. has moved well beyond HIV and hepatitis: Yescarta and Tecartus brought in about $2.0 billion in 2024 sales, and Trodelvy added about $1.3 billion, showing real oncology scale.
These drugs serve different patients, clinics, and payer rules, so the mix is true diversification into a new therapeutic area, not just a line extension.
Cell therapy market entry
Gilead Sciences, Inc. has moved beyond antivirals into cell therapy with Yescarta and Tecartus, targeting hematologic cancers in hospital and oncology-center settings. In fiscal 2025, the franchise generated about $1.9 billion, showing real diversification into a new product class. Yescarta alone has topped $1 billion in annual sales, proving scale in a highly specialized market.
COVID-19 treatment position
Veklury (remdesivir) gives Gilead Sciences, Inc. a pandemic-response antiviral that is separate from HIV and hepatitis C, so it broadens the company’s revenue base into acute infectious disease care. In 2025, Veklury stayed a key part of Gilead Sciences, Inc.'s non-HIV portfolio, used for hospitalized and high-risk COVID-19 patients. This is diversification in the Ansoff sense: the same drug platform reaches a new, time-sensitive market need, not just chronic-therapy demand.
Pulmonary arterial hypertension and angina
In 2025, Gilead Sciences, Inc. reported $28.8 billion in product sales, and Letairis and Ranexa showed its reach beyond antivirals into pulmonology and cardiology. Letairis addressed pulmonary arterial hypertension, while Ranexa treated chronic angina, so both tapped different prescribers, patients, and reimbursement paths. That diversification lowered dependence on one disease area, even as both faced generic pressure.
- Letairis: pulmonary arterial hypertension.
- Ranexa: chronic angina.
- Different markets, prescribers, patients.
- Legacy diversification beyond antivirals.
Serious fungal infection therapy
AmBisome, Gilead Sciences, Inc.'s liposomal amphotericin B, pushes the company into invasive fungal infection care, a non-core area next to HIV and liver disease. In 2025, Gilead Sciences, Inc. reported $28.8 billion in product sales, so this adds a smaller but real infectious-disease niche.
This diversification broadens Gilead Sciences, Inc. across more sub-specialties, and AmBisome helps reduce reliance on the biggest franchises. It also gives exposure to severe hospital-use antifungal therapy, where demand is tied to immunocompromised and ICU patients.
- Non-core, but adjacent to infectious disease
- Expands beyond HIV and liver disease
Gilead’s Growth Engine Is Spreading Beyond Antivirals
Gilead Sciences, Inc. is diversifying beyond antivirals through cell therapy, oncology, and hospital care. In fiscal 2025, Yescarta and Tecartus generated about $1.9 billion, while Trodelvy added about $1.3 billion, proving scale in a new therapeutic area. Veklury and AmBisome widen the mix further across acute infectious disease and antifungal care.
| Asset | 2025 sales | Area |
|---|---|---|
| Yescarta/Tecartus | ~$1.9B | Cell therapy |
| Trodelvy | ~$1.3B | Oncology |
| Veklury | Not disclosed | COVID-19 |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.